Drug Trial Radar · NCT00124020
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Last checked: Nov 20, 2026Latest source record: Jan 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
771
Actual
Start
Jan 2005
Primary completion
May 2007
Study completion May 2007
Sponsor
- Lead sponsor
- Cumberland PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 26, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug, telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
Conditions
- Bacterial Pneumonia
Interventions
TelavancinDrug
Telavancin 10 mg/kg/day IV for up to 21 days
VancomycinDrug
Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical ResponseTime frame: 7-14 days following end of antibiotic treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sheba Medical Center, Infectious Disease Unit
Tel HaShomer, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.